Abstract
Background: Clozapine induced granulocytopenia has gained wide attention and effective monitoring has been able to prevent a number of untoward deaths. However, other myelodysplasias induced by Clozapine are still unrecognized and unreported. Another clinical complication of Clozapine is eosinophilia. However, this entity is unrecognized as the focus is mostly on granulocytopenia and neutropenia.
Objective: To describe a case of Clozapine induced eosinophilia without any other clinical or biochemical abnormalities induced by Clozapine.
Methodology: The file records of a patient with Schizoaffective disorder who developed eosinophilia while receiving Clozapine were studied and analyzed.
Results: The patient with Schizoaffective disorder who was on Clozapine with stringent monitoring developed eosinophilia with eosinophil counts rising up to 2850, with a fall in neutrophil counts up to 2320, all of which was reversed after stopping Clozapine.
Conclusion: Clozapine induced eosinophilia should also be considered as one of the important side effects along with neutropenia and leukopenia. Along with neutropenia and leukopenia it might be a manifestation of undergoing immunological abnormality associated with Clozapine.
Keywords: Agranulocytosis, clozapine, eosinophilia, neutropenia, schizoaffective disorder, second generation antipsychotics.
Current Psychopharmacology
Title:Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Volume: 5
Author(s): Deepak Moyal, Amit Khanna, Vishal Dhiman and Aninda Sidana
Affiliation:
Keywords: Agranulocytosis, clozapine, eosinophilia, neutropenia, schizoaffective disorder, second generation antipsychotics.
Abstract: Background: Clozapine induced granulocytopenia has gained wide attention and effective monitoring has been able to prevent a number of untoward deaths. However, other myelodysplasias induced by Clozapine are still unrecognized and unreported. Another clinical complication of Clozapine is eosinophilia. However, this entity is unrecognized as the focus is mostly on granulocytopenia and neutropenia.
Objective: To describe a case of Clozapine induced eosinophilia without any other clinical or biochemical abnormalities induced by Clozapine.
Methodology: The file records of a patient with Schizoaffective disorder who developed eosinophilia while receiving Clozapine were studied and analyzed.
Results: The patient with Schizoaffective disorder who was on Clozapine with stringent monitoring developed eosinophilia with eosinophil counts rising up to 2850, with a fall in neutrophil counts up to 2320, all of which was reversed after stopping Clozapine.
Conclusion: Clozapine induced eosinophilia should also be considered as one of the important side effects along with neutropenia and leukopenia. Along with neutropenia and leukopenia it might be a manifestation of undergoing immunological abnormality associated with Clozapine.
Export Options
About this article
Cite this article as:
Moyal Deepak, Khanna Amit, Dhiman Vishal and Sidana Aninda, Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder, Current Psychopharmacology 2016; 5 (1) . https://dx.doi.org/10.2174/2211556005666160310001856
DOI https://dx.doi.org/10.2174/2211556005666160310001856 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mapping Myeloperoxidase to Identify its Promiscuity Properties Using Docking and Molecular Dynamics Simulations
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology New Antiviral Nucleoside Prodrugs Await Application
Current Medicinal Chemistry Role of Chymase in Preeclampsia
Current Vascular Pharmacology Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Flunarizine Dihydrochloride Nanoemulsion for Migraine Nasal Drug Delivery: Fabrication, Characterization and In Vitro Study
Drug Delivery Letters Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Recent Clinical Evidence for the Treatment of Osteoarthritis: What we have Learned
Reviews on Recent Clinical Trials Pentraxin 3 Serum Levels in Celiac Patients: Evidences and Perspectives
Recent Patents on Food, Nutrition & Agriculture Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology The Long Way to Objectify Organ Damage Related to Cocaine Abuse: Oxidative Stress is the Main Culprit
Mini-Reviews in Organic Chemistry Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Anterior Uveitis with Negative Work-up: Giant Cell Arteritis Remains the Pet Peeve
Current Rheumatology Reviews Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Current Vascular Pharmacology